Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma



Summary

Immune effector cell-associated enterocolitis (IEC-associated enterocolitis) is an emerging complication following CAR-T therapy for multiple myeloma. Characterized by diarrhea, abdominal pain, and potential intestinal inflammation, its management mirrors approaches for other CAR-T toxicities like cytokine release syndrome. Early recognition and differentiation from other causes of colitis is crucial. Treatment often involves supportive care like intravenous fluids and anti-diarrheal medications. Severe cases may require immunosuppression with corticosteroids or TNF-alpha inhibitors. Further research is needed to optimize prevention and management strategies for this potentially serious complication.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!